Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine versus midazolam in treatment-resistant depression
ChiCTR2000037607Phase 3Recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of esketamine and midazolam in treatment-resistant depression (TRD) (2 arms), sponsored by The Affiliated Brain Hospital of Guangzhou Medical University. Primary endpoints: Efficacy and Safety. Started Dec 2020; status: recruiting.
02
Drugs
esketaminemidazolam
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2000037607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037607.